Tonix Pharmaceuticals Holding Corp. TNXP
2.87 USD -0.07 (-2.55%)
As ofNov 18, 2026, 2:07 PM EST
2.77 Day range 2.98
2.77 52-week range 20.56
- YTD
- -81.66%
- 1 year
- -82.43%
News
benzinga.com Tonix Pharmaceuticals Q3 2026 Earnings Call Transcript Tonix Pharmaceuticals (NASDAQ:TNXP) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…benzinga.com Tonix Pharmaceuticals Q3 EPS $(2.89) Misses $(2.31) Estimate, Sales $17.200M Beat $16.717M Estimate Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.89) per share which missed the analyst consensus estimate of $(2.31) by 25.11 percent. This is a 19.5 percent increase over losses…
benzinga.com Tonix Pharma Presents Data From Analysis Of Phase 3 RELIEF And RESILIENT Studies Of TONMYA For Treatment Of Fibromyalgia In Adults, At IASP 2026 World Congress TONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studiesTonix…
benzinga.com Canaccord Genuity Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $18 Canaccord Genuity analyst Gary Nachman initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces Price Target of $18.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…benzinga.com Tonix Pharmaceuticals To Present Effects Of TONMYA On Fibromyalgia Symptoms And Physical Function At The World Congress On Pain, October 26-30 TONMYA was approved by the U.S. Food and Drug Administration on August 15, 2025, and commercially launched in the U.S. on November 17, 2025.Poster Presentation DetailsTitle: Cyclobenzaprine HCl…
